NASDAQ · SMTI
Healthcare · Medical - Instruments & Supplies
$35.05
Up+$0.00 (+0.00%)
Updated Oct 8, 2026, 9:46 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SMTI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
SMTI closed at $35.05 after 21 trading sessions, up 0.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $34.97 | $35.105 | $34.97 | $35.05 | 136.15K |
| Oct 6, 2026 | $35.09 | $35.09 | $34.95 | $35.00 | 155.59K |
| Oct 5, 2026 | $34.74 | $35.08 | $34.74 | $35.00 | 228.59K |
| Oct 2, 2026 | $34.88 | $34.89 | $34.63 | $34.85 | 341.85K |
| Oct 1, 2026 | $35.12 | $35.12 | $34.79 | $34.88 | 541.82K |
| Sep 30, 2026 | $35.09 | $35.17 | $35.04 | $35.14 | 167.01K |
| Sep 29, 2026 | $35.1625 | $35.1625 | $35.04 | $35.09 | 85.41K |
| Sep 28, 2026 | $35.08 | $35.18 | $35.07 | $35.10 | 95.09K |
| Sep 25, 2026 | $35.01 | $35.11 | $34.97 | $35.06 | 161.79K |
| Sep 24, 2026 | $35.09 | $35.20 | $35.07 | $35.10 | 109.15K |
| Sep 23, 2026 | $35.28 | $35.28 | $35.05 | $35.15 | 141.94K |
| Sep 22, 2026 | $35.02 | $35.34 | $35.02 | $35.28 | 130.2K |
| Sep 21, 2026 | $35.07 | $35.17 | $35.01 | $35.17 | 68.53K |
| Sep 18, 2026 | $34.98 | $35.13 | $34.935 | $35.07 | 271.14K |
| Sep 17, 2026 | $35.23 | $35.27 | $34.98 | $34.98 | 66.07K |
| Sep 16, 2026 | $35.13 | $35.185 | $35.08 | $35.10 | 116.2K |
| Sep 15, 2026 | $34.71 | $35.155 | $34.71 | $35.11 | 196.21K |
| Sep 14, 2026 | $34.90 | $35.09 | $34.84 | $34.98 | 153.83K |
| Sep 11, 2026 | $35.21 | $35.24 | $34.91 | $34.92 | 190.67K |
| Sep 10, 2026 | $34.87 | $35.05 | $34.87 | $35.03 | 227.49K |
| Sep 9, 2026 | $35.08 | $35.09 | $34.92 | $35.03 | 171.75K |
The latest Smart Investors Daily articles mentioning SMTI.
Company
Market Activity
Research & News
SMTI research
Company profile and research snapshot.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 17, 2026 | Freedom Broker | Buy | — |
| Apr 15, 2026 | Lake Street | Buy | — |
| Jan 26, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.02 by 350 percent. This is a 78.26 percent increase over losses of $(0.23) per share from the
Yahoo · Aug 8, 2026
Surgical revenue grew 15% as wound care stabilized ahead of $350M Sanara deal.
Yahoo · Jul 30, 2026
Moby summary of MiMedx Group, Inc.'s Q2 2026 earnings call
SeekingAlpha · Jul 30, 2026
MiMedx Group is acquiring Sanara Medtech for $350 million, transforming its business amid operational turmoil. Read more on MDXG and SMTI stocks here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SMTI.
No results
No recent SID articles mention SMTI.
